Investing in the
Life Sciences Revolution

Innovation in Healthcare

Rooted in Research
Driven by Data
Confirmed by Returns

Learn More

Mission & Values

Great medicines make great investments, and Casdin Capital invests in all aspects of today’s Life Sciences revolution.

The companies we work with are putting to use the incredible knowledge base unlocked by the accelerating capability to read and manipulate molecular information. Spanning Healthcare, Biotechnology, Synthetic Biology, and Technology, our sector is dynamic and complex.

Casdin Capital approaches this space by partnering with companies and building positions to create value and open new opportunities. Big returns require patience and persistence, and strong relationships. Due to decades of participation and practice, Casdin Capital is among the few expert investors in the field. Yet our basic formula remains the same: Take aim at big markets; Invest in great ideas and great teams; Stay focused; Avoid hubris.

Words We Live By:

Farsighted

Interactions and decisions need to be made with a multi-year view.

1/7

Words We Live By:

Knowledgeable

Be the expert in everything we do, know all the variables.

1/7

Words We Live By:

Reflective

Employ adaptive learning and be self-demanding.

1/7

Words We Live By:

Consistent

Excellence is not an act but a habit. We are what we repeatedly do.

1/7

Words We Live By:

Disciplined

Be productive but controlled, work hard and remain focused on vision. 

1/7

Words We Live By:

Engaged

Immerse yourself as a participant not merely a spectator.

1/7

Words We Live By:

Principled

Moral & Intellectual integrity. Be Honest, Positive, Productive, Humble.

1/7

Expertise

Healthcare

Molecular Medicine is the future of modern Healthcare

And the advances and products we are invested in represent a paradigm shift that is already moving markets. New diagnostic platforms will continue to expand the ability to identify patients earlier and at a molecular level. Physicians increasingly can target disease with more effective precision-based therapies and leverage molecular-based approaches transforming the morbidity and mortality of disease. The speculation phase is over and the impact will be game-changing, underpin every aspect of care, rapidly changing traditional business models. Casdin Capital knows the space, and who will be empowered and who will ultimately be disrupted.

Click Here to See Opportunities

in Healthcare

Our Focus

Providers, Services, Payers

Expertise

Biotechnology

Genomics is a free-market success story based on the unlocking of the human genome,

making the early promise of Biotechnology a reality. The tools and data now underlie the next generation of great medicines. With its remarkable benefit to society, a direct result of partnerships between the science and investment communities, life-saving medicines and profit will never be mutually exclusive. It’s been an exciting ride so far. And it has only just begun.

Click Here to See Opportunities

in Biotechnology

Our Focus

Life Science Tools, Diagnostics, Drug Developers

Expertise

Synthetic Biology

Healthcare is not the only application for the key advances in genetic engineering.

Genomics is embedded in the most significant current approaches to increasing food production, disease resistance livestock, and sustainable production of materials and specialty chemicals. While these advances will soon underpin areas like the global food supply, Casdin Capital is well-versed in the current ethical and scientific concerns, particularly around genetically modified foods (GMOs). The ways forward are not uncomplicated, but Life Sciences must be part of the solution to the growing demand for food and the new environmental challenges that face us all.

Click Here to See Opportunities

in Synthetic Biology

Our Focus

Agriculture, Live Stock Management, Synthetic Biology, Specialty Chemicals

Expertise

Technology

In Life Sciences, Information is King.

At Casdin Capital, we invest in information platforms whose processing power and data analysis unlock the blueprint for all life. Our approach is simple: Carefully fund, through strategic investments and private partnerships, companies innovating from the numbers and turning them into meaningful products. The data-driven revolution in health care continues, and the era of precision medicine, its transformations, and its disruptions, is already changing modern medicine across the globe. Casdin Capital, uniquely positioned at the crossroads where the science and investment communities meet, is one of the industry’s few seasoned, trusted partners.

Click Here to See Opportunities

in Technology

Our Focus

Capturing, Storing, Processing Data

Meet The Team

Great investing begins with great people, whose Passion and Dedication, Integrity and Intellectual Curiosity, Market Savvy and Client Commitment drives our success.

View Full Team

Our Ventures

Meet a few of the companies who share our vision and are already transforming Life Sciences

23andMe

Biotechnology and its constituents are now at the epicenter of the life science industry.

4D Molecular Therapeutics

4D Molecular Therapeutics have engineered more than 1 billion viral vectors (carriers of targeted gene therapies) which can be optimized and customized to target both rare and large market diseases affecting any tissue or cell type in the body. Their extensive collection of intellectual property is coupled with expanding capabilities in cGMP manufacturing. Both in vivo (in human) and ex vivo (external to humans such as cell cultures) capabilities exist.

908 devices

At the heart of 908 systems are molecular traps a thousand times smaller than those in conventional mass spectrometers.

A2 Biotherapeutics

A2 Biotherapeutics identifies the differences that distinguish tumor cells from normal cells and then targets them by mimicking the natural, selective and cellular killing activities of our immune system. They engineer T cells that are optimized for identifying tumor cells with high accuracy which results in selectively killing the targets versus compromising healthy cells. Their platform targets solid tumors of many forms via the combination of activators/blockers.

AbSci

AbSci represents the future biopharmaceuticals. This startup is based in Vancouver, WA and leverages advanced metabolic strain laboratory culture and bioprocessing and purification methods. The result is highly efficient and cost-effective development of pharmaceutical therapies.

Adaptive Biotechnologies

Adaptive is translating the brilliance of the adaptive immune system with a powerful platform.

Affinia

Affinia is leveraging its proprietary platform for rationally designed novel, second-generation AAV vectors and therapies. Affinia is building a gene therapy company to broaden the reach of gene therapies by leveraging a discovery platform to engineer novel AAV vectors that overcome the limitations of conventional approaches. Addressing the field’s challenges, from tissue selectivity and immunogenicity, to manufacturing yields, and payload capacity, Affinia AAV vectors and gene constructs broaden the reach of gene therapies to meaningful numbers of patients.

Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease.

Aledade

The founding principle of Aledade stems from thousands of conversations with stakeholders from across the country: primary care providers are the foundation of an efficient and effective health care system.

AmplifyBio

AmplifyBio combines the strength and experience of multi-disciplinary teams to advance translational science, cell and gene therapies and next-generation medicines by offering pre-clinical models and support services to support customers in finding success through fast, efficient and safe drug development. The experienced team will work to create and optimize new platforms and technologies, focus on enabling the research, development and production of next-generation therapies and work at solving the challenges of scaling complex therapies.

Other ventures